- Home
- SBT vs KYTX Comparison
SBT vs KYTX Comparison
Compare SBT & KYTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBT
- KYTX
- Stock Information
- Founded
- SBT 1984
- KYTX 2018
- Country
- SBT United States
- KYTX United States
- Employees
- SBT N/A
- KYTX N/A
- Industry
- SBT Savings Institutions
- KYTX
- Sector
- SBT Finance
- KYTX
- Exchange
- SBT Nasdaq
- KYTX NYSE
- Market Cap
- SBT 244.9M
- KYTX 242.1M
- IPO Year
- SBT 2017
- KYTX 2024
- Fundamental
- Price
- SBT $4.79
- KYTX $4.35
- Analyst Decision
- SBT
- KYTX Buy
- Analyst Count
- SBT 0
- KYTX 5
- Target Price
- SBT N/A
- KYTX $23.40
- AVG Volume (30 Days)
- SBT 25.9K
- KYTX 237.0K
- Earning Date
- SBT 10-30-2024
- KYTX 11-13-2024
- Dividend Yield
- SBT N/A
- KYTX N/A
- EPS Growth
- SBT N/A
- KYTX N/A
- EPS
- SBT 0.12
- KYTX N/A
- Revenue
- SBT $67,988,000.00
- KYTX N/A
- Revenue This Year
- SBT N/A
- KYTX N/A
- Revenue Next Year
- SBT $6.68
- KYTX N/A
- P/E Ratio
- SBT $40.36
- KYTX N/A
- Revenue Growth
- SBT N/A
- KYTX N/A
- 52 Week Low
- SBT $4.40
- KYTX $4.32
- 52 Week High
- SBT $6.01
- KYTX $30.60
- Technical
- Relative Strength Index (RSI)
- SBT 52.14
- KYTX 33.83
- Support Level
- SBT $4.76
- KYTX $5.01
- Resistance Level
- SBT $4.95
- KYTX $5.62
- Average True Range (ATR)
- SBT 0.07
- KYTX 0.39
- MACD
- SBT 0.01
- KYTX -0.03
- Stochastic Oscillator
- SBT 44.83
- KYTX 2.19
About SBT Sterling Bancorp Inc.
Sterling Bancorp Inc is a unitary thrift holding company. Its primary business is the operation of its wholly-owned subsidiary, Sterling Bank, through which it offers a range of loan products to the residential and commercial markets, as well as retail banking services. The products and services offered by the bank include saving and current accounts, demand and term deposits, payment cards, trade finance, fund transfer, treasury and cash management. It provides services such as construction loans, residential real estate, commercial real estate, commercial lines of credit and other consumer loans.
About KYTX KYVERNA THERAPEUTICS INC
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.